Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Kay's Better Balance - Sweet BBQ Snack Mix (1 Bag)
Popular Articles

ASH And EHA Jointly Announce Translational Research Training In Hematology Program
In an effort to foster global biomedical research that will ultimately lead to new and improved treatments for patients with blood diseases, the American Society of Hematology (ASH) and the European Hematology Association (EHA) have collaborated to create the Translational Research Training in Hematology (TRTH) program. This program will provide promising translational investigators an opportunity to undertake intensive training in the causes, diagnosis, and experimental treatment of hematologic disorders from some of the most recognized names in the field.

New Centre In London To Accelerate Personalized Mental Health Care
A powerful new research facility at the heart of King"s Health Partners Academic Health Sciences Centre has been launched by Professor Dame Sally C Davies, Director General of Research and Development and Chief Scientific Adviser, Department of Health. The Biomedical Research Centre (BRC) Nucleus is funded by a ÷£3M infrastructure grant from South London and Maudsley Charitable Funds (÷£1.8M) and Guy"s and St Thomas" Charity (÷£1.2M) to create a unique centre housing key translational initiatives to support the development of novel therapies and treatments for mental health and related disorders.
News of the day
Poor Working Conditions For Docs May Affect Quality Of Care
"Adverse working conditions for primary care doctors, including time pressures and an unfavorable organizational culture, may lead to stress, burnout, and ultimately to lower quality patient care, a new study found," MedPage Today reports. The study, published in the July 7 issue of The Annals of Internal Medicine, found that "53.1% of primary care physicians reported time pressure during physical examinations, while 48.1% reported chaotic working environments. Only 23.7% felt that quality was strongly emphasized in their practices. ... Moreover, 48.8% described their jobs as moderately or highly stressful, while 26.5% reported burnout, and 30.1% said they were at least moderately likely to leave their practices within two years." The authors wrote that the findings "are disturbing at a time when recruitment and retention in primary care are of major concern."
Sexual Health

New Broad-Spectrum Vaccine To Prevent Cervical Cancer Induces Strong Responses In Animals

Mice and rabbits immunized with a multimeric-L2 protein vaccine had robust antibody responses and were protected from infection when exposed to human papillomavirus (HPV) type 16 four months after vaccination, according to a new study published in the May 26 online issue of the Journal of the National Cancer Institute. Current HPV L1-based vaccines are almost 100% protective against infection by the two HPV types that are responsible for 70% of all cervical cancer cases world wide. However, the existing vaccines provide limited protection against the other HPV types that cause cancer. With that limitation in mind, Richard Roden, Ph.D., of the Johns Hopkins University in Baltimore, and colleagues have been working on an alternate vaccine that is based on the HPV minor capsid protein L2, which is highly conserved between HPV types. Previous experiments showed that the L2 protein induced only a weak antibody response in animals. In the current study, Roden and colleagues linked together a short segment of the L2 protein from several HPV types to generate a single multimeric L2 fusion protein. They tested the ability of this multimeric-L2 protein to induce antibody responses in animals and its ability to protect them from subsequent infection with HPV type 16. Mice immunized with the multimeric L2 vaccine developed robust antibody responses against all of the HPV types tested, although the antibody titer was still lower than the type-restricted responses following vaccination with an existing HPV L1-based vaccine. When a multimeric L2 vaccine was delivered with a potent adjuvant to stimulate the immune response, such as alum, the vaccinated animals were able to resist infection by HPV16. "Clinical studies are warranted to assess the safety and immunogenicity of multitype L2 vaccines in alum and other adjuvant formulations," the authors write. "If an L2 vaccine were proven effective in people, its simpler manufacturing process could make the local production of such a vaccine highly feasible, which might achieve the goal of producing it at sustainable prices in emerging countries and lead to its widespread implementation in the developing world." In an accompanying editorial, F. Xavier Bosch, M.D., Ph.D., of the Catalan Institute of Oncology, in Barcelona, Spain, reviews the strengths of the current HPV vaccines but notes that they are too expensive to be used in much of the world and do not protect against enough HPV types. A broad-spectrum vaccine, such as the one being developed by Roden and colleagues, could solve those problems. The new data represent a meaningful step forward, Bosch says. "The results open the door to a novel family of second generation HPV vaccines with significant potential value in the public health horizon," the editorialist writes. "As soon as appropriate, Phase 1 trials in humans should be initiated." The clinical evaluation of new products, however, will likely take years. During this time, the currently available vaccines should be used as widely as possible, according to the editorialists. Citations: Article: "Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines." Jagu et al J Natl Cancer Inst 2009, 101: 782-792. Editorial: "Broad-Spectrum Human Papillomavirus Vaccines: New Horizons but One Step at a Time." Bosch, F.X. J Natl Cancer Inst 2009, 101: 771-773 Journal of the National Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009